

# A REVIEW STUDY ON THE COMPARATIVE ANALYSIS OF SAFETY AND EFFECTIVENESS OF MRI CONTRAST AGENTS

Srishti <sup>1</sup>, Pankaj Kumar Dutt <sup>2</sup>, Sumit Singh <sup>3</sup>,  
Shariq Ahmad Lone <sup>4</sup> and Keshchandra Singh <sup>5</sup>

<sup>1</sup> Assistant Professor, School of Medical and Allied Sciences, Sanskriti University, Mathura.

<sup>2</sup> Lecture, Department of Radiology, COER University, Roorkee.

<sup>3</sup> Student, M.Sc. MIT, Santosh Deemed to be University.

<sup>4</sup> Tutor, School of Paramedical and Allied Health Sciences, Al-Karim University, Katihar, Bihar.

<sup>5</sup> Assistant Professor, School of Nursing, Sanskriti University, Mathura.

## Abstract

Magnetic Resonance Imaging (MRI) contrast agents, particularly those based on gadolinium (GBCAs), are pivotal in enhancing diagnostic accuracy. This article provides a comparative analysis of the safety and effectiveness of various GBCAs, highlighting their clinical applications, associated risks, and recommendations for use. The focus is on recent advancements, safety profiles, and the impact of these agents on diagnostic confidence. Gadolinium-based contrast agents (GBCAs) have revolutionized MRI by improving the visibility of internal structures. However, concerns regarding their safety, particularly in patients with renal impairment, necessitate a thorough examination of their comparative effectiveness and safety. This article reviews the current literature to provide insights into the use of different GBCAs, their associated risks, and guidelines for their safe administration. While their use is generally safe, particularly with macrocyclic agents, careful consideration must be given to patients with renal impairment. Ongoing research is essential to further understand the long-term effects of gadolinium retention and to develop safer contrast agents.

**Keywords:** Gadolinium, Nephrogenic systemic fibrosis, Hepatobiliary, Chronic Kidney Disease.

## INTRODUCTION

Magnetic Resonance Imaging (MRI) is a powerful diagnostic tool widely used in clinical practice due to its ability to provide detailed anatomical images with excellent soft tissue contrast. Contrast agents play a crucial role in enhancing the visibility of specific tissues or organs during MRI examinations, aiding in the detection and characterization of various pathological conditions.

The development and utilization of MRI contrast agents have significantly advanced medical imaging, enabling clinicians to obtain more accurate and comprehensive diagnostic information. However, the choice of contrast agent can have profound implications for both the efficacy and safety of MRI examinations.

The efficacy of an MRI contrast agent is determined by its ability to enhance image contrast, improve diagnostic accuracy, and facilitate the detection of abnormalities such as tumors, inflammation, and vascular lesions. Various factors, including relaxivity, pharmacokinetics, and tissue specificity, influence the efficacy of contrast agents and their suitability for different imaging applications.

While efficacy is essential, ensuring patient safety is paramount in the selection of MRI contrast agents. Adverse reactions to contrast agents, although rare, can range from mild allergic reactions to severe life-threatening complications such as nephrogenic systemic fibrosis (NSF) in patients with

impaired renal function. Thus, evaluating the safety profile of contrast agents is crucial to minimize the risk of adverse events and ensure patient well-being.

### Types of Gadolinium-Based Contrast Agents:

GBCAs are categorized into linear and macrocyclic agents. Linear GBCAs have a higher risk of dissociation and gadolinium retention, while macrocyclic GBCAs are more stable and less likely to release gadolinium ions.

- **Linear GBCAs:** Include agents such as gadodiamide and gadopentetate dimeglumine, which are associated with higher risks of nephrogenic systemic fibrosis (NSF) and gadolinium retention in the brain and other organs.
- **Macrocyclic GBCAs:** Examples include gadobutrol (Gadovist) and gadoteric acid (Dotarem). These agents form tighter complexes with gadolinium, reducing the risk of dissociation and subsequent adverse effects.
  - **Gadoteric Acid (Dotarem and Clariscan):** Widely used due to its safety profile and effectiveness in enhancing image quality. It is especially preferred in central nervous system (CNS) imaging.
  - **Gadobutrol (Gadovist):** Administered at slightly higher doses, it is noted for providing excellent image quality, particularly useful in complex diagnostic scenarios.

In this comparative study, we aim to evaluate the efficacy and safety of commonly used MRI contrast agents, focusing on their performance in clinical practice. By systematically analyzing the available literature and clinical data, we seek to provide clinicians with evidence-based insights to guide their selection of contrast agents and optimize the balance between diagnostic efficacy and patient safety.

Through this comprehensive evaluation, we endeavor to contribute to the ongoing efforts to enhance the quality and safety of MRI examinations, ultimately improving patient care and clinical outcomes.

### Comparative Analysis of Safety and Effectiveness of MRI Contrast Agents

MRI contrast agents, particularly those based on gadolinium (GBCAs), have been widely studied to understand their safety and effectiveness. Here's an overview of key findings from several journal articles on this topic:

#### 1. Safety of Gadolinium-Based Contrast Agents

**Safety Concerns:** Gadolinium is inherently toxic and not naturally occurring in the body. Chronic exposure can lead to retention in vital organs, including the brain, causing symptoms like fatigue, cognitive impairments, and dermatological issues. This has raised significant safety concerns, especially with linear GBCAs, which are more prone to dissociation and retention compared to macrocyclic GBCAs.

**Nephrogenic Systemic Fibrosis (NSF):** One of the most severe adverse effects associated with GBCAs is NSF, primarily in patients with advanced kidney disease. However, Group II (macrocyclic) GBCAs have shown an exceedingly low risk of inducing NSF, making them the preferred choice for patients with compromised kidney function. Macrocyclic agents are preferred due to their lower NSF risk. **Gadolinium Retention:** Research indicates that all patients exposed to MRI contrast agents exhibit some level of gadolinium retention. Studies highlight the need for further investigation into the long-term biological effects of gadolinium and the potential for destabilization of MRI contrast agents by ordinary human metabolites.

## 2. Effectiveness of Different GBCAs

**Diagnostic Confidence:** The use of GBCAs significantly increases diagnostic confidence. In a study involving various GBCAs, it was found that contrast-enhanced MRI increased diagnostic confidence in 96.2% of cases, with a substantial improvement in diagnostic accuracy.

### Clinical Application:

**Dosing and Administration:** The recommended dose for most GBCAs is 0.1 mmol/kg, with specific adjustments for agents like gadoxetic acid used in hepatobiliary imaging. The elimination half-life of GBCAs varies with renal function, necessitating different intervals between doses based on the patient's kidney health.

**CNS Imaging:** Gadoteric acid (Dotarem) and gadobutrol (Gadovist) are frequently used due to their high efficacy in enhancing CNS images, leading to improved diagnostic accuracy and confidence.

**Hepatobiliary Imaging:** Gadoxetic acid, a liver-specific GBCA, provides excellent liver imaging but is limited in use due to specific safety concerns in patients with severe renal impairment.

## 3. Recommendations for Use

**For Patients with Chronic Kidney Disease (CKD):** Professional guidelines suggest using macrocyclic GBCAs to minimize NSF risk. In patients with advanced CKD or those undergoing dialysis, careful consideration and individual assessment are essential to balance the diagnostic benefits against potential risks.

**General Population:** For the general population, especially those with normal renal function, GBCAs are considered safe when used appropriately. Continuous monitoring and adherence to recommended dosing guidelines help mitigate risks associated with gadolinium retention and toxicity.

## CONCLUSION

This article aim was to provide a comprehensive review of the current understanding of GBCA safety and effectiveness, helping clinicians make informed decisions in their use.

MRI capabilities are improved by gadolinium. Most patients can safely receive it in its chelated form at the recommended dosages. A tiny subgroup of patients with severe chronic kidney disease (CKD) have been shown to have nephrogenic systemic fibrosis; these cases are primarily associated with Group I GBCAs. Over the past ten years, there has been a greater knowledge of the function of chelating agents, which has resulted in the adoption of procedures that have virtually eradicated the occurrence of NSF.

Particularly with the more recent and secure Group II GBCAs, the low risk of GBCA administration in high-risk patients (such as those with advanced CKD) should be weighed against the possibility of preventing patients from receiving a clinically necessary contrast-enhanced MRI test. While MRI contrast agents significantly enhance diagnostic capabilities, their use must be carefully managed to ensure patient safety. Macrocyclic GBCAs are generally preferred due to their lower risk of adverse effects like NSF. Continuous research and updated clinical guidelines are crucial to optimizing the use of these agents, ensuring their benefits outweigh the risks.

## References

- 1) Kanal E. Gadolinium based contrast agents (GBCA): safety overview after 3 decades of clinical experience. *Magn Reson Imaging* 2016; 34 (10): 1341–5.
- 2) BMC Medical Imaging - Patterns of use, effectiveness, and safety of gadolinium contrast agents: A European prospective cross-sectional multicentre observational study (BioMed Central).
- 3) Texas Heart Institute Journal - Gadolinium-Based Contrast Agents: Updates and answers to typical questions regarding gadolinium use (Allen Press).
- 4) *Frontiers in Toxicology - Magnetic Resonance Imaging Contrast Agents: The safety of gadolinium* (Frontiers).
- 5) Runge VM. Safety of magnetic resonance contrast media. *Top Magn Reson Imaging* 2001; 12 (4):309–14.
- 6) Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, et al. Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. *Can J Kidney Health Dis* 2018; 5:2054358118778573.
- 7) European Medicines Agency. PRAC confirms restrictions on the use of linear gadolinium agents [Internet]. Available from: [https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-prac-confirms-restrictions-use-linear-gadolinium-agents\\_en.pdf](https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-prac-confirms-restrictions-use-linear-gadolinium-agents_en.pdf) [2017 Jul 7; cited 2021 Mar 3].
- 8) Behzadi AH, Zhao Y, Farooq Z, Prince MR. Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. *Radiology* 2018; 286(2):471–82.
- 9) Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. *Am J Dermatopathol* 2001; 23(5):383–93.
- 10) McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY. Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. *Radiology*. 2018; 289:517–34.
- 11) ACR Committee on Drugs and Contrast Media, ACR Manual on Contrast Media. Version 10.3. 2020. [https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast\\_Media.pdf](https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf). Accessed 14 April 2020.
- 12) FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs. 2017. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-identifies-no-harmful-effects-date-brain-retention-gadolinium>. Accessed 2 Mar 2020.
- 13) Clariscan Summary of Product Characteristics. 2020. <https://mri.cts-mrp.eu/Human/>. Accessed 3 Mar 2020.
- 14) Dotarem drug information. French Public Drug Database. 2020. <http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69244971>. Accessed 3 Mar 2020.
- 15) Abbas M, Omer A, Hamad M. Adequacy of clinical information on radiology request cards from medical assessment unit, Clinical Audit. *Nucl Med Biomed Imaging*. 2016; 1:5–6.